Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04231084 · ClinicalTrials.gov registry record · Phase 4
Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 115
- Enrollment target
NCT04231084: Completed Phase 4 study, sponsored by Brigham and Women's Hospital.
NCT04231084 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 115 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04231084, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 115 participants
- Enrollment target
Study Summary
The overarching goal of this study is to examine the acute vasoreactive response to both inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity to disease severity and PH phenotype.
Primary Outcome
The primary outcome will be change in mean pulmonary artery pressure (mmHg) from baseline to after 5-minutes of inhaled vasodilator.
Interventions
- DRUG Vasodilator testing (Inhaled Nitric Oxide)
- DRUG Vasodilator testing (Inhaled Epoprostenol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 4 |
What the finished NCT04231084 record still lists
NCT04231084 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Vasodilator testing (Inhaled Nitric Oxide) is the first listed.
NCT04231084 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04231084 about?
NCT04231084 is a clinical study titled "Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide". The overarching goal of this study is to examine the acute vasoreactive response to both inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity to disease severity and...
What is the current status of trial NCT04231084?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 115 participants. The study started on 2021-01-15. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT04231084?
The interventions under investigation include: Vasodilator testing (Inhaled Nitric Oxide) (DRUG), Vasodilator testing (Inhaled Epoprostenol) (DRUG).
Who is sponsoring clinical trial NCT04231084?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04231084's enrollment target sits among peer trials
115 718th of 2000 higher than 1,281 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI